Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia: the JALSG-ALL97 study

Autor: Yuji Kishimoto, Masako Iwanaga, Shigeo Horiike, Masayuki Kato, Motohiro Tsuzuki, Kazunori Ohnishi, Hirokazu Okumura, Yasushi Miyazaki, Shuichi Miyawaki, Yasunori Ueda, Yasuhiro Maeda, Noriko Usui, Jin Takeuchi, Fumiharu Yagasaki, Tohru Sakura, R Ohno, Itsuro Jinnai, Taiichi Kyo, Kosuke Tsuboi, Tomoki Naoe
Rok vydání: 2010
Předmět:
Zdroj: International Journal of Hematology. 92:490-502
ISSN: 1865-3774
0925-5710
DOI: 10.1007/s12185-010-0672-z
Popis: We designed a treatment protocol for newly diagnosed adult acute lymphoblastic leukemia (ALL) in the pre-imatinib era, employing intensified consolidation therapy with a total of 330 mg/m² doxorubicin and adopting slightly modified induction and maintenance regimen of the CALGB 8811 study. Of 404 eligible patients (median age 38 years, range 15-64 years), 298 (74%) achieved complete remission (CR). The 5-year overall survival (OS) rate was 32%, and the 5-year disease-free survival (DFS) rate was 33%. Of 256 Philadelphia chromosome (Ph)-negative patients, 208 (81%) achieved CR and the 5-year OS rate was 39%, and 60 of them underwent allogeneic-hematopoietic stem cell transplantation (allo-HSCT) from related or unrelated donors during the first CR, resulting in 63% 5-year OS. Of 116 Ph-positive patients, 65 (56%) achieved CR and the 5-year OS rate was 15%, and 22 of them underwent allo-HSCT from related or unrelated donors during the first CR, resulting in 47% 5-year OS. In Ph-negative patients, multivariate analysis showed that older age, advanced performance status and unfavorable karyotypes were significant poor prognostic factors for OS and higher WBC counts for DFS. The present treatment regimen could not show a better outcome than that of our previous JALSG-ALL93 study for adult ALL.
Databáze: OpenAIRE
Externí odkaz: